GeneDx Investor Class Action Deadline Approaching
Investors must designate a lead plaintiff by August 3, 2026, in a class-action lawsuit filed against GeneDx Holdings Corp. Allegations include misleading statements regarding company performance and financials.
The law firm Faruqi & Faruqi LLP is investigating potential claims against GeneDx Holdings Corp. (NASDAQ: WGS). A federal securities class action has been filed against the company, and investors are reminded that the deadline to seek the role of lead plaintiff is August 3, 2026.
The complaint alleges that GeneDx and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose material information. Specifically, the lawsuit claims the company may have misled investors about the importance of Fabric Genomics and its impact on the company's margins. Furthermore, the complaint asserts that the company's average reimbursement rates were not as "durable" as previously disclosed.
Following these disclosures, GeneDx's stock price fell over 49% in early May 2026 after the company reported weaker-than-expected first-quarter results and cut its 2026 guidance. The company also reported an average reimbursement rate below expectations and a significant goodwill impairment charge related to the Fabric Genomics acquisition.
Faruqi & Faruqi LLP urges investors who purchased GeneDx securities between April 16, 2025, and May 4, 2026, and suffered losses to contact the firm to discuss their legal rights. The decision to serve as lead plaintiff does not affect an investor's ability to share in any potential recovery.